Table 1 Baseline Characteristics of the participants
Variables | Cisplatin Group n = 200 n (%) | Non-Cisplatin Group n = 200 n (%) |
|---|---|---|
1 Age (yrs)a | 56 (11.9) | 55 (9) |
2 Males | 108 (54%) | 104 (52%) |
3 Time to VTE (days)a | 58 (17) | 56 (13) |
4 Stage | ||
Early | 10 (5%) | 12 (6%) |
Locally advanced | 86 (43%) | 92 (46%) |
Metastatic | 104 (52%) | 96 (48%) |
5 Presence of CVC | 58 (29%) | 55 (27%) |
6 Surgery in 2 months | 44 (22%) | 56 (28%) |
7 ECOG poor | 16 (8%) | 12 (6%) |
8 Khorana Risk | ||
low | 39(19.5%) | 55 (27.5%) |
intermediate | 129 (64.5%) | 125 (62.5%) |
high | 32 (16%) | 20 (10%) |
9 Use of GCSF | ||
never | 88 (44%) | 86 (43%) |
<50% of cycles | 71 (35.5%) | 81 (40.5%) |
>50% of cycles | 6 (3%) | 24 (12%) |
All cycles | 35 (17.5%) | (9 9.5%) |